# Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

> **NCT04410796** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 571 (estimated)

## Conditions studied

- Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04410796
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-28
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 571 (ESTIMATED)
- **Last updated:** 2025-11-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04410796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04410796, "Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04410796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*